Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Revenue (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Revenue for 9 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 23.93% to $57.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $236.2 million, a 47.46% increase, with the full-year FY2025 number at $236.2 million, up 47.46% from a year prior.
  • Revenue was $57.6 million for Q4 2025 at Akebia Therapeutics, down from $58.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $165.8 million in Q4 2022 to a low of $32.6 million in Q1 2024.
  • A 5-year average of $60.3 million and a median of $52.6 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 225.04% in 2021, then crashed 66.11% in 2023.
  • Akebia Therapeutics' Revenue stood at $57.7 million in 2021, then skyrocketed by 187.49% to $165.8 million in 2022, then plummeted by 66.11% to $56.2 million in 2023, then fell by 17.26% to $46.5 million in 2024, then increased by 23.93% to $57.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Revenue are $57.6 million (Q4 2025), $58.8 million (Q3 2025), and $62.5 million (Q2 2025).